SecBot SecBot
8-K ·Filed May 5, 2026

ATRC

AtriCure, Inc.
MIXED
Impact 6/10
Horizondays Processed6mo ago SEC0001323885-26-000018
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The sharp reduction in adjusted EPS guidance despite a strong quarter signals potential margin pressure or increased spending. Watch Q2 2026 results for confirmation of cost trends. The stock may sell off on the guidance cut, but the underlying revenue momentum suggests any dip could be a buying opportunity if margins stabilize.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.01
T+0 close · May 5, 2026 · via day close
Latest settled
+34.81%
T+60 · $37.76
Vs SPY
+32.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $28.01entry
  2. T+1 · 6mo ago 0.00%α +0.33% · $28.01
  3. T+5 · 6mo ago −4.71%α −5.84% · $26.69
  4. T+20 · 6mo ago −6.46%α −9.24% · $26.20
  5. T+60 · 4mo ago +34.81%α +32.75% · $37.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AtriCure reported Q1 2026 revenue of $141.2M (+14.3% YoY) and achieved GAAP net income of $0.1M, beating EPS consensus of -$0.07. However, full-year 2026 adjusted EPS guidance was slashed from $0.09-$0.15 to $0.00-$0.04, overshadowing the strong quarter.

Key Financial Metrics

EPS
$0.00
est −$0.07 · +100.0%
Revenue
$141.2M
+14.3% YoY
Rating
beat
Guidance
$600M-$610M
lowered
Gross Margin
77.4%

Key Facts

  • Q1 2026 revenue $141.2M, +14.3% YoY (12.8% constant currency)
  • Gross margin expanded 246 bps to 77.4%
  • GAAP net income $0.1M vs loss of $6.7M YoY; EPS $0.00 vs consensus -$0.07
  • Adjusted EBITDA $17.1M, +95% YoY
  • FY2026 revenue guidance reaffirmed at $600-$610M
  • FY2026 adjusted EPS guidance lowered from $0.09-$0.15 to $0.00-$0.04

Financial Impact

Guidance cut on EPS from $0.09-$0.15 to $0.00-$0.04 implies ~70% midpoint decline; revenue guidance unchanged.

epsguidance

Risk Factors

  • Full-year EPS guidance cut significantly lower; margin compression risk
  • Selling, general & administrative expenses grew 11% YoY, outpacing revenue growth

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001323885-26-000018
Document: atrc-20260505.htm0001323885-26-000018
Document: 0001323885-26-000018-index-headers.html0001323885-26-000018
Document: 0001323885-26-000018-index.html0001323885-26-000018
Document: 0001323885-26-000018.txt0001323885-26-000018
8-K Data (Synthetic)0001323885-26-000018

US Market Status

Market Closed · Opens in 7h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026